Literature DB >> 18424744

Bactericidal action of a complement-independent antibody against relapsing fever Borrelia resides in its variable region.

Timothy J LaRocca1, Laura I Katona, David G Thanassi, Jorge L Benach.   

Abstract

A single chain variable fragment (scFv) of CB515, a complement-independent bactericidal monoclonal IgM against a relapsing fever Borrelia, was constructed to investigate the region wherein the unique bactericidal function resides. Monomeric CB515 scFv (26 kDa) was capable of binding its Ag on whole organisms and by immunoblot. This binding was shown to be species and serotype-specific to the 19 kDa variable small protein, recognized by its parent monoclonal IgM. A dose-dependent bactericidal effect of the CB515 scFv was detected by direct enumeration of spirochetes. Spirochetes incubated with the CB515 scFv before inoculation into mice grew into escape mutants, whereas spirochetes incubated with an irrelevant scFv developed as the original infecting serotype. This bactericidal effect, as seen at the ultrastructural level, was due to disruption of the outer membrane and to severe membrane blebbing eventually progressing to lysis. These results indicate that the variable region of CB515 is responsible for this bactericidal activity and that the constant region of the Ab is dispensable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18424744     DOI: 10.4049/jimmunol.180.9.6222

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  B1b lymphocyte-derived antibodies control Borrelia hermsii independent of Fcα/μ receptor and in the absence of host cell contact.

Authors:  Matthew J Colombo; David Abraham; Akira Shibuya; Kishore R Alugupalli
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

2.  Antibody Binding to the O-Specific Antigen of Pseudomonas aeruginosa O6 Inhibits Cell Growth.

Authors:  Gabrielle Richard; C Roger MacKenzie; Kevin A Henry; Evgeny Vinogradov; J Christopher Hall; Greg Hussack
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

3.  Phylogenetic analysis of a virulent Borrelia species isolated from patients with relapsing fever.

Authors:  A Toledo; P Anda; R Escudero; C Larsson; S Bergstrom; J L Benach
Journal:  J Clin Microbiol       Date:  2010-05-12       Impact factor: 5.948

4.  A new synthesis for antibody-mediated immunity.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  Nat Immunol       Date:  2011-12-16       Impact factor: 25.606

Review 5.  Anti-bacterial monoclonal antibodies: next generation therapy against superbugs.

Authors:  Hui Wang; Daijie Chen; Huili Lu
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-01       Impact factor: 4.813

6.  Inhibition of Salmonella enterica serovar typhimurium motility and entry into epithelial cells by a protective antilipopolysaccharide monoclonal immunoglobulin A antibody.

Authors:  Stephen J Forbes; Marisa Eschmann; Nicholas J Mantis
Journal:  Infect Immun       Date:  2008-07-14       Impact factor: 3.441

7.  The bactericidal effect of a complement-independent antibody is osmolytic and specific to Borrelia.

Authors:  Timothy J LaRocca; David J Holthausen; Chyongere Hsieh; Christian Renken; Carmen A Mannella; Jorge L Benach
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-19       Impact factor: 11.205

8.  Variable Major Proteins as Targets for Specific Antibodies against Borrelia miyamotoi.

Authors:  Alex Wagemakers; Joris Koetsveld; Sukanya Narasimhan; Melvin Wickel; Kathleen Deponte; Boris Bleijlevens; Seta Jahfari; Hein Sprong; Lyudmila S Karan; Denis S Sarksyan; Tom van der Poll; Linda K Bockenstedt; Adriaan D Bins; Alexander E Platonov; Erol Fikrig; Joppe W Hovius
Journal:  J Immunol       Date:  2016-04-13       Impact factor: 5.422

Review 9.  Pathogenesis of Relapsing Fever.

Authors:  Job Lopez; Joppe W Hovius; Sven Bergström
Journal:  Curr Issues Mol Biol       Date:  2020-12-29       Impact factor: 2.081

Review 10.  Monoclonal antibody-based therapies for microbial diseases.

Authors:  Carolyn Saylor; Ekaterina Dadachova; Arturo Casadevall
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.